The past three decades have witnessed remarkable advances in our ability to target specific
elements of the immune and inflammatory response, fuelled by advances in both …

MicroRNAs (miRNAs) are small noncoding RNAs that broadly affect cellular and
physiological function in all multicellular organisms. Here, the role of miRNAs in …

The failure of anti-CD20 antibody (Rituximab) as therapy for lupus may be attributed to the
transient and incomplete B cell depletion achieved in clinical trials. Here, using an …

Multiple sclerosis (MS) is known to be a partially heritable autoimmune disease. The risk of
developing MS increases from typically 1 in 1,000 in the normal population to 1 in 4 or so for …

In this narrative review, we analyze pre-registration and post-marketing data concerning
hepatotoxicity of all disease-modifying therapies (DMTs) available for the treatment of …

Immunotherapy is the field of immunology that aims to identify treatments for diseases
through induction, enhancement or suppression of an immune response. Immunotherapies …

CAR-T cell therapy targeting CD19 demonstrated strong activity against advanced B cell
leukemia, however shows less efficacy against lymphoma with nodal dissemination. To …

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS)
associated with inappropriate activation of lymphocytes, hyperinflammatory responses …

The global incidence of multiple sclerosis (MS) appears to be increasing. Although it may
not be associated with a high mortality rate, this disease has a high morbidity rate which …

Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS).
More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo …